

1. Record Nr.	UNISA996385126503316
Autore	Fell John <1625-1686.>
Titolo	A specimen of the several sorts of letter given to the University [[electronic resource] /] / by Dr. John Fell, sometime Lord Bishop of Oxford. To which is added the letter given by Mr. F. Junius
Pubbl/distr/stampa	Oxford, : Printed at the Theater, A.D. 1695
Descrizione fisica	[1]+ p
Soggetti	Printing - England - Specimens
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Identified as Wing (2nd ed.) F623 on UMI microfilm "Early English books, 1641-1700" reel 1503. Fragments; consists of t.p., engraved frontispiece of University of Oxford coat of arms and various pages. Reproduction of original in: British Library.
Sommario/riassunto	eebo-0018

2. Record Nr.	UNINA9910971012703321
Titolo	Development of medications for the treatment of opiate and cocaine addictions : issues for the government and private sector / / Carolyn E. Fulco, Catharyn T. Liverman, and Laurence E. Earley, editors ; Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine
Pubbl/distr/stampa	Washington, DC, : National Academy Press, 1995
ISBN	9786610192991 9780309176521 0309176522 9781280192999 1280192992 9780309587914 0309587913 9780585025414 058502541X
Edizione	[1st ed.]
Descrizione fisica	xvii, 250 p. : ill
Altri autori (Persone)	FulcoCarolyn LivermanCatharyn T EarleyLaurence E
Disciplina	616.86/32061
Soggetti	Drug addiction - Treatment Cocaine abuse - Treatment Substance abuse - Treatment
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Committee chairman: Laurence E. Earley. Support for this study was provided by the National Institute on Drug Abuse.
Nota di bibliografia	Includes bibliographical references.
Nota di contenuto	Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector -- Copyright -- Acknowledgments -- Preface -- Note to the Reader -- Contents -- Executive Summary -- STATE OF THE SCIENTIFIC KNOWLEDGE ON

ADDICTION -- NIDA'S MEDICATIONS DEVELOPMENT DIVISION --
EFFECTIVENESS OF TREATMENT -- TREATMENT FINANCING --
TRAINING AND EDUCATION -- FEDERAL REGULATORY ISSUES -- Food
and Drug Administration -- Drug Enforcement Administration -- STATE
REGULATORY ISSUES -- Interim Actions -- Long-Term Actions --
MARKET OBSTACLES AND CREATING INCENTIVES -- Size of the Market
-- Drug Pricing and Intellectual Property Rights -- Societal Stigma --
NEED FOR FEDERAL LEADERSHIP -- CONCLUSIONS -- OPTIONS FOR
FURTHER CONSIDERATION -- REFERENCES -- 1 Introduction -- PUBLIC-
HEALTH REPERCUSSIONS OF ILLICIT DRUG USE -- Health Consequences:
Violence -- Health Consequences: AIDS -- Health Consequences:
Tuberculosis -- Health Consequences: Drug-exposed Infants --
ECONOMIC COSTS OF ILLICIT DRUG USE TO SOCIETY -- EXTENT OF
ILLICIT DRUG USE -- ROLE OF PHARMACOTHERAPY -- REFERENCES -- 2
Overview of the State of Scientific Knowledge Concerning Drug
Addiction -- CONCEPTS OF DRUG ADDICTION -- BIOLOGICAL
CORRELATES AND PSYCHOPHARMACOLOGY OF ADDICTION -- Opiate
Addiction -- Cocaine Addiction -- MDD AND STRATEGIES FOR THE
DISCOVERY OF A COCAINE MEDICATION: DESCRIPTION AND CRITICAL
ANALYSIS -- Introduction -- Source of Compounds -- Medication
Preclinical Screening -- In Vitro Screen-Receptors and Mechanisms of
Action -- In Vivo Screen-Behavioral Tests -- Specific Conclusions and
Recommendations for the MDD -- Clinical Trials -- Human Behavioral
Models -- CONCLUSIONS AND RECOMMENDATIONS -- REFERENCES -- 3
Assessment of the Medications Development Division -- STRUCTURE
AND FUNCTIONS OF THE MEDICATIONS DEVELOPMENT DIVISION.
Mission and History -- Research Focus on Opiates and Cocaine --
Program Objectives -- Organizational Structure -- Budget Process --
Resources and Funding Instruments -- Types of Grants and Contracts
-- Interagency Agreements -- CRADAs -- Screening Agreements --
Training -- RELATIONSHIPS WITH OTHER FEDERAL AGENCIES AND THE
PRIVATE SECTOR -- Food and Drug Administration -- Drug
Enforcement Administration -- Office of Protection from Research Risks
-- Pharmaceutical Industry -- ASSESSMENT OF THE MEDICATIONS
DEVELOPMENT DIVISION -- Staff and Resources -- Drug-Discovery
Programs -- Clinical Trials -- Clinical-Research Training --
Relationships with Regulatory Agencies -- Interaction with the Private
Sector -- SUMMARY -- CONCLUSIONS AND RECOMMENDATIONS --
REFERENCES -- 4 Treatment Setting and Effectiveness -- TREATMENT
SETTING -- Opiate Addiction -- Cocaine Addiction -- DEMOGRAPHIC
AND FINANCIAL PROFILE -- Opiate-Dependent Patients -- Cocaine-
Dependent Patients -- TREATMENT EFFECTIVENESS AND COST-
EFFECTIVENESS -- Methadone Maintenance Treatment -- Effectiveness
-- Cost-Effectiveness -- Cocaine Addiction Treatment -- Effectiveness
-- Cost-Effectiveness -- CONCLUSIONS AND RECOMMENDATION --
REFERENCES -- 5 Treatment Financing and Trends in Health Insurance
-- FINANCING OF TREATMENT -- Financing the Treatment of Opiate
Addiction -- Financing the Treatment of Cocaine Addiction --
FINANCING OF LAAM FOR THE TREATMENT OF OPIATE ADDICTION --
IMPACT OF HEALTH INSURANCE TRENDS ON MEDICATIONS
DEVELOPMENT -- Trends in Drug Abuse Treatment Benefits --
REFERENCES -- 6 Training and Education -- EXPANDING THE CORE OF
RESEARCHERS AND CLINICIANS -- Training Programs -- Fellowships --
Certification -- Conclusions and Recommendations -- INCREASING
KNOWLEDGE AND SKILLS AMONG PRIMARY CARE PHYSICIANS --
Required Education in Medical Schools -- Residency Training.
Continuing Education -- Conclusions and Recommendations --
COMPREHENSIVE DRUG ABUSE CENTERS -- Proposed Model -- Existing

Research and Training Centers -- CSAT Centers -- NIDA Research
 Centers -- Conclusions and Recommendations -- SUMMARY --
 REFERENCES -- 7 Federal Laws and Regulations -- CREATION OF A
 DRUG BY THE PHARMACEUTICAL INDUSTRY -- FOOD AND DRUG
 ADMINISTRATION -- Recent Initiatives to Expedite Availability of New
 Drugs -- Market Exclusivity and Orphan Drug Status -- FDA Guidelines
 on Evaluation of Anti-Addiction Drugs -- DRUG ENFORCEMENT
 ADMINISTRATION -- Scheduling -- Quotas -- Regulatory Authority
 Over Anti-Addiction Drugs In Development -- CONCLUSIONS --
 REFERENCES -- 8 State Laws and Regulations -- STATE REGULATORY
 LANDSCAPE -- Scheduling -- Treatment -- Admission Criteria --
 Staffing Requirements -- Patient Registries -- Drug Screening --
 Medication Take-Home Policies -- Clinical Research -- LAAM: A CASE
 STUDY -- Federal Regulations -- State Regulations --
 Scheduling/Rescheduling -- Treatment Regulations -- Clinic Approval
 -- CONCLUSIONS -- RECOMMENDATIONS -- Interim Actions -- Long-
 Term Actions -- REFERENCES -- 9 Market Obstacles and Creating
 Incentives -- MARKET OBSTACLES TO PRIVATE-SECTOR INVESTMENT --
 Nature and Size of the Market -- Drug Pricing and Intellectual Property
 Rights -- Societal Stigma -- Clinical Research on Anti-Addiction
 Medications -- Product Liability -- NEED FOR FEDERAL LEADERSHIP --
 CONCLUSIONS -- OPTIONS FOR FURTHER CONSIDERATION --
 REFERENCES -- Appendix A Acknowledgements -- Appendix B
 Organization and Mission Statements of NIDA's Medications
 Development Division and Its... -- MEDICATIONS DEVELOPMENT
 DIVISION MISSION STATEMENT -- Biometrics Branch Mission Statement
 -- Chemistry and Pharmaceutics Branch Mission Statement -- Clinical
 Trials Branch Mission Statement.
 Pharmacology and Toxicology Branch Mission Statement -- Regulatory
 Affairs Branch Mission Statement -- Appendix C Diagnostic Criteria for
 Psychoactive Substance Dependence -- Appendix D Survey of
 Pharmaceutical Companies -- ATTACHMENT 1 -- ATTACHMENT 2 --
 Appendix E Model Federal Programs in Pharmaceutical R&D -- D --
 ANTIEPILEPTIC DRUG DEVELOPMENT PROGRAM -- Background --
 Elements of Success -- NATIONAL CANCER INSTITUTE CANCER-DRUG
 DISCOVERY AND DEVELOPMENT PROGRAMS -- Background --
 Preclinical Research -- Clinical Research -- Elements of Success --
 NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES DRUG
 DISCOVERY AND DEVELOPMENT PROGRAMS -- Background --
 Preclinical Research -- Clinical Research -- Elements of Success --
 REFERENCES -- Appendix F Workshop Agenda and Participants --
 WORKSHOP AGENDA -- PARTICIPANT LIST -- Appendix G Health Care
 Reform Legislation -- UNIVERSALITY OF COVERAGE -- PRESCRIPTION
 DRUG BENEFITS -- DRUG ABUSE TREATMENT BENEFITS -- INSURANCE
 REFORM -- FINANCING HEALTH CARE REFORM AND THE FATE OF
 MEDICAID -- CONCLUSIONS -- REFERENCES -- Appendix H Acronyms.

Sommario/riassunto

Pharmacotherapy, as a means of treating drug addiction in combination
 with other treatment modalities, has received too little attention from
 the research community, the pharmaceutical industry, public health
 officials, and the federal government. Medications to combat drug
 addiction could have an enormous impact on the medical consequences
 and socioeconomic problems associated with drug abuse, both for
 drug-dependent individuals and for American society as a whole. This
 book examines the current environment for and obstacles to the
 development of anti-addiction medications, specifically those for
 treating opiate and cocaine addictions, and proposes incentives for the
 pharmaceutical industry that would help overcome those obstacles and
 accelerate the development of anti-addiction medications.

